Bottom line In the 72-week SURMOUNT-5 trial, tirzepatide produced greater average weight loss than semaglutide in adults with obesity or overweight without diabetes. That establishes greater average efficacy under the trial conditions. It does not make tirzepatide the best choice for every patient because treatment selection also depends on indication, contraindications, tolerability, coverage, cardiovascular
